Login to Your Account


TLC and Ablynx agree to jointly develop targeted liposome drug delivery technology

By Dave Silver
Staff Writer

Friday, April 18, 2014

TAIPEI, Taiwan – Taiwan Liposome Co. (TLC) and Ablynx NV are planning to jointly develop a new drug delivery technology combining TLC's immunoliposome platform with Ablynx' antibody-derived nanobody technology that will enable more precisely targeted delivery of liposome-encapsulated cytotoxic compounds to disease sites in cancer patients.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription